Phase 1 study of the aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies

Alisertib, an Aurora kinase A inhibitor, was evaluated in a Phase 1 study in combination with the histone deacetylase inhibitor vorinostat, in patients with relapsed/refractory lymphoid malignancies (N=34; ). Patients received alisertib plus vorinostat in 21-day treatment cycles with escalating dose...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leuk Lymphoma
Main Authors: Siddiqi, Tanya, Frankel, Paul, Beumer, Jan H., Kiesel, Brian F., Christner, Susan, Ruel, Chris, Song, Joo Y., Chen, Robert, Kelly, Kevin R., Ailawadhi, Sikander, Kaesberg, Paul, Popplewell, Leslie, Puverel, Sandrine, Piekarz, Richard, Forman, Stephen J., Newman, Edward M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6982547/
https://ncbi.nlm.nih.gov/pubmed/31617432
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2019.1672052
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados